25Q1 不良率（0.97%）、关注率（1.54%）分别较上年末持平、提升 9bps， 拨备覆盖率、拨贷比分别为 326.08%、3.17%，分别较上年末提升 5.2pc、 提升 7bps。25Q1 信用成本为 1.26%，同比提升 3bps。 证券研究报告 | 季报点评 gszqdatemark 2025 04 29 年 月 日 瑞丰银行（601528.SH） 息差降幅明显收窄，拨备进一步夯实 事件：瑞丰银行披露 2025 年一季报，2025 年一季度实现营收 11.1 亿元， 同比增长 5.12%，归母净利润 4.2 亿元，同比增长 6.69%。2025Q1 末不 良率、拨备覆盖率分别为 0.97%、326.08%，较上年末分别持平、提升 5.2pc。 1、业绩表现：息差降幅同比收窄 25Q1 年营业收入、归母净利润增速分别为 5.12%、6.69%，分别较 24A 下降 10.2pc、下降 4.6pc，其中息差同比降幅收窄、业务成本节约等对业 绩形成正向贡献，具体来看： 1）利息净收入：同比增长 2.68%，较 24A 增速提升 4.3pc，25Q1 净息差 为 1.46%，较 24A 下降 4bps（ ...

证券研究报告：有色金属 | 公司点评报告 发布时间：2025-04-29 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 26.68 | | --- | --- | | 总股本/流通股本（亿股）19.00 | / 16.64 | | 总市值/流通市值（亿元）507 | / 444 | | 52 周内最高/最低价 | 31.30 / 15.61 | | 资产负债率(%) | 47.3% | | 市盈率 | 24.93 | | 第一大股东 | 李金阳 | 研究所 分析师:李帅华 SAC 登记编号:S1340522060001 Email:lishuaihua@cnpsec.com 研究助理:杨丰源 SAC 登记编号:S1340124050015 Email:yangfengyuan@cnpsec.com 赤峰黄金(600988) 25 年一季报点评：静待瓦萨成本企稳，金价上行 公司业绩释放有望加速 l 25 年 Q1 归母净利润 4.83 亿元，同比+141% 公司发布 2025 年一季报，受益黄金价格同比大幅上行，公司业 绩释放出色：营业收入 24.07 亿元，同比增长 3 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][13]. Core Views - The company reported a revenue of 28.88 billion yuan for 2024, a year-on-year decrease of 12.8%, and a net profit attributable to shareholders of 6.67 billion yuan, down 33.4% year-on-year. The performance was below market expectations [2]. - In Q1 2025, the company achieved a revenue of 11.07 billion yuan, a decline of 31.9% year-on-year, with a net profit of 3.64 billion yuan, down 39.9% year-on-year [2]. - The company’s white liquor sales decreased by 16.3% to 139,000 tons in 2024, while the price per ton increased by 3.9% to 203,000 yuan/ton [3]. - The company’s gross profit margin decreased to 73.2% in 2024, down 2.1 percentage points year-on-year, and the net profit margin decreased to 23.1%, down 7.1 percentage points year-on-year [4]. - The company plans to focus on core products and key markets in 2025, aiming for sustainable development while maintaining price stability and channel profitability [4]. Summary by Sections Performance Review - In 2024, the company’s revenue was 28.88 billion yuan, a decrease of 12.8% year-on-year, and the net profit was 6.67 billion yuan, down 33.4% year-on-year. Q1 2025 revenue was 11.07 billion yuan, a decline of 31.9%, with a net profit of 3.64 billion yuan, down 39.9% [2]. Operational Analysis - The company’s white liquor sales fell by 16.3% to 139,000 tons in 2024, with a price increase of 3.9% to 203,000 yuan/ton. Revenue from mid-to-high-end liquor and regular liquor was 24.32 billion yuan and 3.93 billion yuan, respectively, with year-on-year declines of 14.8% and 0.5% [3]. Financial Quality - The company’s net profit margin decreased to 23.1% in 2024, with a gross profit margin of 73.2%. In Q1 2025, the net profit margin was 32.9%, with a gross profit margin of 72.8% [4]. - The company has committed to a cash dividend of no less than 7 billion yuan for 2024-2026, corresponding to a current dividend yield of approximately 6.5% [4]. Profit Forecast and Valuation - The report adjusts the profit forecast for 2025 and 2026, expecting a 23% and 27% decrease in net profit, respectively. The projected revenues for 2025, 2026, and 2027 are expected to decline by 11.0%, increase by 3.0%, and increase by 5.8%, respectively [5].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has shown a revenue growth of 8.5% in 2024, with a total revenue of 73.4 billion RMB and a net profit of 25.9 billion RMB, reflecting a 13.4% increase [7] - The company is experiencing a slowdown in mid-to-low-end liquor sales, while the "Dingcang" series continues to show strong growth potential [7] - The report highlights a proactive approach to managing cash flow and inventory, ensuring healthy channel profits and turnover [7] Financial Summary - Total revenue projections for the company are as follows: 2023A: 6,771 million RMB, 2024A: 7,344 million RMB, 2025E: 7,378 million RMB, 2026E: 7,862 million RMB, 2027E: 8,685 million RMB [1] - Net profit forecasts are: 2023A: 2,282 million RMB, 2024A: 2,589 million RMB, 2025E: 2,617 million RMB, 2026E: 2,842 million RMB, 2027E: 3,205 million RMB [1] - The earnings per share (EPS) estimates are: 2023A: 2.85 RMB, 2024A: 3.24 RMB, 2025E: 3.27 RMB, 2026E: 3.55 RMB, 2027E: 4.01 RMB [1] - The price-to-earnings (P/E) ratios for the years 2025-2027 are projected to be 14.9, 13.7, and 12.2 respectively [7]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [4]. Core Viewpoints - The company experienced a revenue decline of 16.5% year-on-year in Q1 2025, with total revenue reaching 1.61 billion RMB and a net profit of 90 million RMB, down 31.1% year-on-year [2]. - The integration with China Resources Sanjiu is in its final phase, and while short-term performance is under pressure due to channel transformation, there are expectations for improvement as new procurement standards are implemented in Q2 [2][4]. - The company is focusing on brand development and enhancing terminal coverage, particularly for key products like "Kunzhong Medicine 1381" and "777 Xuesaitong Soft Capsules," which are expected to see healthy growth [3]. Summary by Sections Performance Analysis - In Q1 2025, the company reported a revenue of 1.61 billion RMB, a decrease of 16.5% year-on-year, and a net profit of 90 million RMB, down 31.1% year-on-year [2]. - The decline is attributed to multiple factors, including channel transformation and the ongoing integration with China Resources Sanjiu [2]. Brand Development - The company is committed to its brand strategy, focusing on key products to strengthen its position as a leading national medicine brand [3]. - The launch of new packaging for "777 Xuesaitong" is expected to enhance brand recognition and drive sales growth [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of 740 million RMB, 893 million RMB, and 1.072 billion RMB for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 14%, 21%, and 20% [4]. - The earnings per share (EPS) are expected to be 0.98 RMB, 1.18 RMB, and 1.42 RMB for the same years, with corresponding price-to-earnings (PE) ratios of 17, 14, and 12 [4].

Investment Rating - The report maintains a "Buy" rating for the company, expecting continued performance resilience and growth potential in the coming years [6]. Core Insights - The company reported a total revenue of 4.004 billion RMB for 2024, reflecting a year-on-year growth of 13.24%, while the net profit attributable to shareholders decreased by 14.28% to 781 million RMB [3][10]. - In Q1 2025, the company achieved a revenue of 1.286 billion RMB, a slight increase of 1.41%, with a net profit of 331 million RMB, down 8.47% year-on-year, aligning with expectations [3][4]. - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 285 million RMB, with a payout ratio of 36.55% [3]. Performance Analysis - The profit performance in 2024 was weaker than revenue growth, primarily due to increased brand marketing investments [4]. - The company experienced a significant revenue increase of 35% in Q4 2024, driven by strong customer loyalty and enhanced brand presence [4]. - The gross margin for 2024 was 77%, a decrease of 1.6 percentage points, while the net profit margin fell by 6.3 percentage points to 19.5% due to rising sales and management expenses [4]. Brand Development - The KENT&CURWEN brand is positioned as a second growth curve for the company, with new store openings and a focus on appealing to Gen Z consumers [5]. - The brand aims to enhance its visual identity and market presence, with new product launches planned for Spring/Summer 2025 [5]. Profit Forecast and Valuation - The company is expected to achieve net profits of 714 million RMB, 874 million RMB, and 1.038 billion RMB for 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 14, 11, and 9 [6][10]. - The main brand is anticipated to continue gaining influence, supported by the successful launch of international new brands and improved operations [6].

盈利预测、估值与评级 根据公司在手订单及最新业务进展，下调公司 2025-2026 年盈利 分别至 8.7（-57%）/6.1（-157%）亿元，新增 2027 年盈利为 6.8 亿元，对应 EPS 为 3.12/2.19/2.45 元，当前股价对应 PE 分别为 37/52/47 倍，维持"买入"评级。 风险提示 订单确认不及预期；订单需求不及预期；新业务开拓不及预期。 业绩简评 2025 年 4 月 28 日，公司发布 2024 年年报及 2025 年一季报。2024 全年公司实现营业收入 98.30 亿元，同比+21.53%；实现归母净利 润 9.26 亿元，同比+1.31%；2025 年一季度实现营业收入 22.29 亿 元，同比+0.47%，实现归母净利润 1.62 亿元，同比-37.69%，业绩 符合预期。 经营分析 大额减值拖累 24 年及 25Q1 业绩，持续推进 HJT 工艺进步：公司 2024 年全年计提减值 5.2 亿元，其中信用减值 3.9 亿元，较 2023 年同期增加 297%；2025Q1 计提信用减值 1.8 亿元，主要是受行业 影响公司部分订单执行放缓或停滞及个别客户继续履约 ...

2025 年 4 月 28 日，公司披露 24 年年报及 25 年一季报。1）24 年实现营收 14.2 亿元，同比-49.7%；实现归母净利 0.1 亿元， 同比-97.7%。2）25Q1 实现营收 3.4 亿元，同比-30.3%；实现归 母净利 0.3 亿元，同比-56.8%。业绩仍处于承压阶段。 分产品来看，24 年内参/酒鬼/湘泉/其他系列分别实现营收 2.4/8.3/0.8/2.7 亿元，同比-67%/-49%/+8%/-31%，其中销量分 别-56%/-46%/+19%/-20%，吨价分别-25%/-6%/-10%/-13%，吨价 下行致使内参/酒鬼/其他系列毛利率分别-2.4/-2.9/-10.1pct。 期内公司仍着手去化渠道遗留库存问题，聚焦消费者扫码、宴席 活动，期内宴席、消费者扫码有明显增长。公司也阶段性开始梳 理产品架构，酒鬼酒 SKU 压减 50%，构建"2+2+2"战略单品体 系，即 2 个战略单品（内参、红坛）、2 个重点单品（妙品、透明 装）、2 个馥郁香基础单品（内品、湘泉）。 分渠道来看，24 年线上/线下分别实现营收 1.9/12.3 亿元，同比 -34%/-51%。此外 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][3] Core Insights - The company achieved a revenue of 10.778 billion yuan in 2024, representing a year-on-year growth of 21.04%, with a net profit of 1.552 billion yuan, up 30.00% [1][3] - The company continues to experience robust growth, driven by its main brand and sub-brands, with a significant increase in online sales [2][12] - The company is focusing on a big product strategy and expanding its sub-brand matrix, indicating strong long-term growth potential [3][15] Financial Performance Summary - In 2024, the company reported a total revenue of 10.778 billion yuan, with a year-on-year growth of 21.04% [4][11] - The net profit attributable to the parent company for 2024 was 1.552 billion yuan, reflecting a growth of 30.00% [4][11] - The company’s gross margin improved to 71.39% in 2024, an increase of 1.46 percentage points from the previous year [14] - The company’s operating cash flow for 2024 was 1.107 billion yuan, a decrease of 24.63% year-on-year due to increased payments for goods and promotional expenses [14] Revenue Breakdown - Online sales accounted for 95.06% of total revenue in 2024, with online revenue reaching 10.234 billion yuan, up 23.68% [2][12] - The main brand, Proya, generated 8.581 billion yuan in revenue, representing 79.69% of total revenue, with a growth of 19.55% [2][12] - The skincare category contributed 90.19 billion yuan, accounting for 83.78% of total revenue, with a growth of 19.31% [2][12] Future Projections - The company expects revenues of 12.469 billion yuan, 14.257 billion yuan, and 16.093 billion yuan for 2025, 2026, and 2027 respectively [3][4] - Projected net profits for the same years are 1.840 billion yuan, 2.150 billion yuan, and 2.441 billion yuan [3][4] - The report anticipates a decrease in the price-to-earnings ratio from 20 times in 2025 to 15 times in 2027, indicating improving valuation [3][4]

亚信安全（688225.SH） 网安高质量发展，数智业务全面拥抱 AI 2025 年 04 月 29 日 投资评级：买入（维持） | 日期 | 2025/4/28 | | --- | --- | | 当前股价(元) | 22.89 | | 一年最高最低(元) | 29.98/10.10 | | 总市值(亿元) | 91.56 | | 流通市值(亿元) | 47.86 | | 总股本(亿股) | 4.00 | | 流通股本(亿股) | 2.09 | | 近 3 个月换手率(%) | 176.62 | 股价走势图 数据来源：聚源 -40% 0% 40% 80% 120% 2024-04 2024-08 2024-12 亚信安全 沪深300 计算机/软件开发 亚信科技在稳固运营商业务基本盘的同时，加速三新业务的开拓，并全面拥抱 AI，已沉淀一整套全面且高效的大模型交付能力体系，涵盖从需求分析、模型训 练、性能优化到最终上线部署的每一个关键环节。自重组事项完成后，公司启动 网络安全业务与数智业务在研发、销售、经营管理等方面的全面协同，构建云网 安一体化的核心竞争力。 风险提示：行业增度下降风险；核心技术人员流失风险； ...